Experimental drug slows progression of early Alzheimer's disease by 60%, study finds
https://ift.tt/xdLf2wV Eli Lilly's experimental drug donanemab slowed the progression of Alzheimer's by 60% for patients in the earliest stages of the brain-wasting disease, according to trial data presented at a medical meeting on Monday.
from France 24 - International breaking news, top stories and headlines https://ift.tt/iweTqsP
from France 24 - International breaking news, top stories and headlines https://ift.tt/iweTqsP
Commentaires
Enregistrer un commentaire